Skip to Content
Morningstar

CRISPR Therapeutics AG CRSP Stock Quote

Morningstar Rating
| Rating as of

NASDAQ: CRSP

Show Full Chart
Market Closed

| Currency in USD

  • Last Close 42.92
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Growth
  • Day Range 41.46  –  43.32
  • Year Range 38.94  –  72.00
  • Market Cap 3.4099 Bil
  • Volume / Avg 1.5 Mil /  960,756.4
  • Price / Sales 19.82
  • Price / Book 1.88
  • Forward Div Yield —
  • Trailing Div Yield —

Morningstar‘s Stock Analysis CRSP

Valuation
Currency in —
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Positive Outlook for CRISPR Therapeutics' Gene Editing Technology; Shares Very Undervalued

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

CRISPR Therapeutics is a clinical-stage gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company's proprietary platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CRSP

More

Company Profile CRSP

Business Description

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Contact
Baarerstrasse 14
Zug, CH-6300, CHE
Sector Healthcare
Industry Biotechnology
Employees 458

Related Articles CRSP

Stock Strategist

5 Most Undervalued Defensive Stocks

Well-known names such as Moderna, CVS, and Kraft Heinz are trading at discounted prices.
Jülide Sengil
Our Picks

7 Undervalued Biotech Stocks

Even with biotech stocks performing well in the bear market, names including Moderna and Incyte are trading at a discount.
Jülide Sengil
Sustainability Matters

11 Stocks to Examine Through a Sustainability Lens

Investors can use ESG information in many useful ways.
Adam Fleck
Our Picks

6 Undervalued Biotech Stocks for 2023

These stocks from the Morningstar US Biotechnology Index look cheap.
Maggie Guidici
Investing Specialists

Ever-Evolving ESG, Warren Buffett, and Which Stocks Are Beating the Market

We review the top stocks, funds, and exchange-traded funds this week as well as share updates you can make to your portfolio.
Jessica Bebel
Market Update

Why These Biotech Stocks Are Outperforming the Market

Recession-resistant stocks include undervalued names like Moderna and CRISPR.
Lauren Solberg
Market Update

Markets Brief: Are We Headed for an Earnings Recession?

Despite rising worries of recession and a bear market, stock analysts have become more optimistic. That could be a risk for investors.
Sandy Ward
Market Update

Markets Brief: Ahead of the Next CPI Report, More Signs Inflation is Peaking

Still, the Fed is expected to continue its aggressive push to raise interest rates.
Sandy Ward

Related News CRSP

More

Competitors & Peers CRSP

More on CRSP’s Competitors & Peers

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of CRSP’s competitive advantage.

CRISPR Therapeutics AG

XNAS: CRSP

Vertex Pharmaceuticals Inc

XNAS: VRTX

Moderna Inc

XNAS: MRNA

BioNTech SE ADR

XNAS: BNTX
Price
42.94345.15103.08109.33
Currency
USDUSDUSDUSD
Change
+$0.53 (1.25%) −$2.68 (0.77%) −$0.23 (0.22%) −$3.42 (3.03%)
Market Cap
3.41 Bil89.08 Bil39.23 Bil26.21 Bil
Industry
Biotechnology Biotechnology Biotechnology Biotechnology
Sector
Healthcare
Healthcare
Healthcare
Healthcare

* Trading data in this section is delayed by at least 15 minutes.

FAQs for CRISPR Therapeutics AG Stock

No. CRSP does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CRSP’s market cap is 3.41 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CRSP’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CRSP’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CRSP’s historical performance against its industry peers and the overall market.